Bypass Budget asks for $9.988B to boost payline, enhance clinical research, deliver on Moonshot promises

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The 2024 Bypass Budget submitted by NCI Acting Director Douglas Lowy asks for $9.988 billion—$2.222 billion more than the 2023 document submitted by then director Ned Sharpless. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Jacquelyn Cobb
Associate Editor
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
Historically, the research initiatives of the Foundation for AIDS Research (amfAR) have focused on finding a cure for HIV. Four decades of HIV research have reshaped our understanding of the immune system, and insights from HIV have been leveraged in adjacent fields, including cancer immunology. Innovation can be bi-directional and reciprocal. Seminal findings in cancer immunology have also furthered understanding of HIV biology. 
Jacquelyn Cobb
Associate Editor
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login